Chief executive of Cancer Research UK, Michelle Mitchell, said, "The UK should be striving for world-leading cancer outcomes. All cancer patients, no matter where they live, deserve to receive the highest quality care. But this research shows that UK patients are treated with chemotherapy and r...
Using haematopoietic growth factors to increase dose intensity has not consistently improved survival [103] but may limit the morbidity of myelosuppression. Prophylactic antibiotics are recommended for patients at risk of neutropenic sepsis [121] but care should be taken that the chosen antibiotic does ...
ACCESS is a real-world innovation programme evaluating the impact of adding G360 to the current invasive diagnostic pathway for suspected BTC/PC in 6 hospitals in West London; (n=240).Methods:This is a pre-planned interim analysis of the first sequential 65 pts with G360 in ACCESS. ...
All patients with a possible diagnosis of a primary bone tumour should be referred urgently under the 2 week wait pathway to a fully accredited bone sarcoma MDT [4,45,46]. This core principle is embedded in the NICE ‘Improving Outcomes for People with Sarcomas’ guidance [47], ‘Children ...
practice of unselected coagulation screening and advise selective screening in those with a positive personal or family bleeding history, patients on anticoagulants and those patients with a relevant medi- cal history including cancer, liver disease, sepsis and dis- seminated intravascular coagulation [...
As a general rule, cold burn injuries are initially managed conservatively to allow the wound to demarcate, unless severe infection with sepsis develops [22]. Systemic antibiotics are required only in the presence of proven infection, trauma or cellulitis (evidence grade 1C). If the wound is ...
The qSOFA score can be calculated using basic parameters of clinical assessment and aims to identify patients at increased risk of death due to sepsis.17 NEWS is a scoring system (score 0–20) based upon routine clinical observations reflecting the individual's physiological response to illness. ...
During follow-up, 6 (18%) patients discontinued patiromer due to gastrointestinal side effects, 3 no longer required the binder because of decrease in RAASi use and 2 patients died (one each from stroke and sepsis). One patient was switched to an alternative potassium binder. As of 1st ...
pathway from local hospital guidelines and assesses their variation. Sepsis kills 46,000 people per year in the UK with societal costs of up to £10 billion. Therefore, there is a clinical need for an optimized pathway. By applying our method in this field, we were able to assess the ...